Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 known ✓ | P22460 | 2/20 | 0.31 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.31 |
| ▸ | CHRNA1 known ✓ | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG known ✓ | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 known ✓ | P11230 | 1/20 | 0.31 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.31 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.31 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.31 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.31 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.31 |
| ▸ | CHRND known ✓ | Q07001 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14136210 | 0.97 | FDPS (0.35) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL1897139 | 0.97 | — | — | |
| SCHEMBL827253 | 0.97 | — | — | |
| SCHEMBL1339269 | 0.94 | — | — | |
| Bromide SCHEMBL2225990 | 0.91 | — | — | |
| Formamide SCHEMBL11268980 | 0.83 | LMNA (0.36) | FDPSCHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL11570562 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL27515815 | 0.77 | FDPS (0.33) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6987884 | 0.75 | CHRNA7 (0.39) | SMN1; SMN2FDPSCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL28544917 | 0.74 | MC4R (0.40) | SMN1; SMN2CYP3A4CYP2D6CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112442087-A | Preparation method and application of ionic phosphoramidite ligand | 上海簇睿低碳能源技术有限公司 | 2021-03-05 | — | — | CN | claimed |
| WO-2020192280-A1 | DOUBLE BASIC-FUNCTIONALIZED IONIC LIQUID WITH SURFACE ACTIVITY AND PREPARATION METHOD THEREFOR | 枣庄学院 | 2020-10-01 | — | — | WO | claimed |
| CN-116731031-A | Down-praline derivative and application thereof | 贵州药法自然医药科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-115785806-B | Photovoltaic glass coated with organic-inorganic hybrid coating and processing technology thereof | 鼎钰玻璃(扬州)有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-115785806-A | Photovoltaic glass coated with organic-inorganic hybrid coating and processing technology thereof | 鼎钰玻璃(扬州)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-3354648-B1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | CHENGDU ZENITAR BIOMEDICAL TECH CO LTD (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-108349959-B | 4-substituted coumarin derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-112442087-A | Preparation method and application of ionic phosphoramidite ligand | 上海簇睿低碳能源技术有限公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2020192280-A1 | DOUBLE BASIC-FUNCTIONALIZED IONIC LIQUID WITH SURFACE ACTIVITY AND PREPARATION METHOD THEREFOR | 枣庄学院 | 2020-10-01 | — | — | WO | disclosed |
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-10-04 | — | — | US | disclosed |
| WO-1995017095-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5017572-A | CALCIUM ANTAGONIST | DELALANDE S.A. (FR) | 1991-05-21 | — | — | US | disclosed |
| US-4139620-A | HYPOTENSIVE AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4104380-A | Dibenzyl glycolic acid derivatives | WARNER-LAMBERT COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4096331-A | HYPOTENSIVE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1978-06-20 | — | — | US | disclosed |
| US-4076937-A | Dibenzyl glycolic acid derivatives | WARNER-LAMBERT COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4073917-A | Local anesthetics tertiary aminoalkoxyphenyl ethers | ASTRA LAKEMEDEL AKTIEBOLAG (SW) | 1978-02-14 | — | — | US | disclosed |
| US-4018766-A | BRONCHODILATORS | WARNER-LAMBERT COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-3937832-A | ADMINISTERING | SOCIETE ANONYME DITE: HEXACHIMIE (FR) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | MAP4, TUBA3C, ABCC1 | KCNA5 817/4885KCNH2 2006/4885CHRNA1 4069/4885 |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | MAP4, TUBA3C, ABCC1 | KCNA5 817/4885KCNH2 2006/4885CHRNA1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.